BACKGROUND: The study aimed to evaluate the impact of integrating molecular classification with imaging-based preoperative staging on risk stratification prediction in endometrial cancer patients in accordance with ESGO/ESTRO/ESP (European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology) 2021 guidelines. METHODS: A retrospective cohort of 143 endometrial cancer patients was analyzed to assess changes in preoperative risk stratification after incorporating molecular classification into clinical evaluation. Preoperative clinical staging was primarily based on transvaginal ultrasound imaging. The overall agreement between preoperative risk group estimates (with/without molecular classification) and final postoperative outcomes was assessed using weighted Cohen's Kappa, with bootstrap 95% confidence intervals and quadratic weights. RESULTS: The addition of molecular classification significantly improved preoperative risk stratification accuracy (from 59.4 to 73.4%), particularly for patients post-operatively classified as high-risk. Kappa values indicated an improvement in overall agreement between preoperative and postoperative risk stratification following the addition of molecular classification, from 0.551 (95% CI: 0.430-0.671) to 0.767 (95% CI: 0.675-0.849). The non-overlapping confidence intervals indicated statistical significance. Preoperative assessment without molecular input tended to underestimate risk stratification. However, 26.6% of patients remained misclassified due to other factors, mostly within the intermediate and high-intermediate risk groups. CONCLUSIONS: Incorporating molecular classification enhances preoperative risk stratification and has the potential to tailor surgical treatment. Further validation through prospective multicentric studies is needed to support our findings.

Department of Informatics and Quantitative Methods Faculty of Informatics and Management University of Hradec Kralove Hradec Kralove Czech Republic

Department of Non medical Studies Faculty of Medicine in Hadec Kralove Charles University Hradec Kralove Czech Republic

Department of Obstetrics and Gynecology Charles University Faculty of Medicine in Hradec Kralove Hradec Kralove Czech Republic

Department of Oncology and Radiotherapy University Hospital Hradec Kralove Hradec Kralove Czech Republic

Department of Preventive Medicine Faculty of Medicine in Hradec Kralove Charles University Hradec Kralove Czech Republic

The Fingerland Department of Pathology Charles University Faculty of Medicine in Hradec University Hospital Hradec Kralove Kralove Hradec Kralove Czech Republic

Zobrazit více v PubMed

Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63. 10.3322/caac.21834. PubMed

Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2021;31(1):12–39. 10.1136/ijgc-2020-002230. PubMed

Ribeiro-Santos P, Martins Vieira C, Viana Veloso GG, et al. Tailoring endometrial cancer treatment based on molecular pathology: current status and possible impacts on systemic and local treatment. Int J Mol Sci. 2024;25(14): 7742. 10.3390/ijms25147742. PubMed PMC

Leone FPG, Timmerman D, Bourne T, et al. Terms, definitions and measurements to describe the sonographic features of the endometrium and intrauterine lesions: a consensus opinion from the international endometrial tumor analysis (IETA) group. Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol. 2010;35(1):103–12. 10.1002/uog.7487. PubMed

Frühauf F, Dvořák M, Haaková L, et al. Ultrasound staging of endometrial cancer - recommended methodology of examination. Ceska Gynekol. 2014;79(6):466–76. PubMed

WHO Classification of Tumours Editorial Board. Female genital tumours [Internet]. Lyon (France): International Agency for Research on Cancer; 2020 [cited 2025 Apr 6]. (WHO classification of tumours series, 5th ed.; vol. 4). https://tumourclassification.iarc.who.int/chapters/34

Matias-Guiu X, Anderson L, Buza N, Ellenson LH, Fadare O, Ganesan R, Ip PPC, Palacios J, Raspollini MR, Werner HMJ, Lax SF, McCluggage WG. Endometrial cancer histopathology reporting guide. 5th ed. Sydney: International Collaboration on Cancer Reporting; 2024.

Cho KR, Cooper K, Croce S, et al. International society of gynecological pathologists (ISGyP) endometrial cancer project: guidelines from the special techniques and ancillary studies group. Int J Gynecol Pathol. 2019;38(Supplement 1):S114–22. 10.1097/PGP.0000000000000496. PubMed PMC

Dundr P, Cibula D, Doležel M, et al. Molecular testing in endometrial carcinoma (Joint recommendation of Czech oncological society, oncogynecological section of the Czech gynecological and obstetrical society, society of radiation oncology, biology and physics, and the society of Czech Pathologists). Cesk Patol. 2021;57(3):181–7. PubMed

Fleiss JL, Levin B, Paik MC. Statistical methods for rates and proportions. 1st ed. Hoboken: Wiley; 2003. 10.1002/0471445428.

Sokolova M, Lapalme G. A systematic analysis of performance measures for classification tasks. Inf Process Manag. 2009;45(4):427–37. 10.1016/j.ipm.2009.03.002.

Knez J, Sobocan M, Belak U, et al. Pre-treatment risk assessment of women with endometrial cancer: differences in outcomes of molecular and clinical classifications in the Slovenian patient cohort. Radiol Oncol. 2021;56(1):76–82. 10.2478/raon-2021-0036. PubMed PMC

Eriksson LSE, Nastic D, Lindqvist PG, et al. Combination of proactive molecular risk classifier for endometrial cancer (ProMisE) with sonographic and demographic characteristics in preoperative prediction of recurrence or progression of endometrial cancer. Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol. 2021;58(3):457–68. 10.1002/uog.23573. PubMed PMC

Cabrera S, Bebia V, López-Gil C, et al. Molecular classification improves preoperative risk assessment of endometrial cancer. Gynecol Oncol. 2024;189:56–63. 10.1016/j.ygyno.2024.07.003. PubMed

Betella I, De Vitis LA, Calidona C, Multinu F, Colombo N. Letter to the editor-the new FIGO staging system for endometrial cancer: is the paradigm shift clinically feasible? Int J Gynaecol Obstet. 2024;164(1):364–5. 10.1002/ijgo.15265. PubMed

Sehnal B, Hruda M, Matej R, Robova H, Drozenova J, Pichlik T, Halaska MJ, Rob L, Dundr P. New FIGO 2023 staging system of endometrial cancer: an updated review on a current hot topic. Geburtshilfe Frauenheilkd. 2025;85:405–16. 10.1055/a-2494-8395. PubMed PMC

Alcázar JL, Orozco R, Martinez-Astorquiza Corral T, et al. Transvaginal ultrasound for preoperative assessment of myometrial invasion in patients with endometrial cancer: a systematic review and meta-analysis: TVS for preoperative assessment of MI in endometrial cancer. Ultrasound Obstet Gynecol. 2015;46(4):405–13. 10.1002/uog.14905. PubMed

Alcázar JL, Pérez L, Güell O, et al. Diagnostic performance of transvaginal ultrasound for detecting cervical invasion in women with endometrial carcinoma: a systematic review and meta-analysis. J Ultrasound Med. 2019;38(1):179–89. 10.1002/jum.14682. PubMed

Borges AC, Veloso H, Galindo P, et al. Role of ultrasound in detection of lymph-node metastasis in gynecological cancer: systematic review and meta‐analysis. Ultrasound Obstet Gynecol. 2024;64(2):155–63. 10.1002/uog.27633. PubMed

Kato MK, Fujii E, Yamaguchi M, et al. Excellent concordance of the molecular classification between preoperative biopsy and final hysterectomy in endometrial carcinoma. Gynecol Oncol. 2024;190:139–45. 10.1016/j.ygyno.2024.08.016. PubMed

Berek JS, Matias-Guiu X, Creutzberg C, et al. FIGO staging of endometrial cancer: 2023. Int J Gynecol Obstet. 2023;162(2):383–94. 10.1002/ijgo.14923. PubMed

Chacon E, Boria F, Lyer RR, et al. SENECA study: staging endometrial cancer based on molecular classification. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2024;34(9):1313–21. 10.1136/ijgc-2024-005711. PubMed

ASTEC study group, Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009;373(9658):125–36. 10.1016/S0140-6736(08)61766-3. PubMed PMC

Siegenthaler F, Imboden S, Büchi C, et al. Added prognostic value of sentinel lymph node mapping in endometrial cancer to molecular subgroups. Gynecol Oncol. 2025;193:12–9. 10.1016/j.ygyno.2024.12.014. PubMed